Sermorelin

Pediatric Growth-Hormone-Deficiency Diagnostic Research

The pediatric GH-deficiency diagnostic indication is the original FDA-approved use of sermorelin. Geref Diagnostic (NDA 19-863, 0.05 mg base/amp, approved December 28, 1990) was authorized for evaluating the ability of pituitary somatotrophs to secrete growth hormone in clinical workup of suspected GHD in children^[4][5].

The diagnostic provocation protocol used intravenous sermorelin at low microgram-per-kilogram dosing in fasting subjects, with serial venous sampling of plasma GH at fixed timepoints over approximately 60 minutes. The rapid post-injection GH pulse and short half-life produce a clean provocation signal that, in the pediatric endocrinology literature, has been reported to yield fewer false-positive responses than older alternative provocation tests (insulin-tolerance test, arginine, clonidine, levodopa). Aimaretti et al. 2000 reported on the use of a sermorelin-plus-arginine provocation test in retesting young adults with childhood-onset GHD as part of the transition-age diagnostic workflow^[6].

The diagnostic indication and supporting pediatric endocrinology literature are extensive across multiple decades. Geref Diagnostic was the only sermorelin formulation continuously authorized for the diagnostic provocation indication in the United States until the December 2008 commercial discontinuation. The molecule itself remains available through 503A compounding pharmacies under the regulatory pathway discussed in the FDA-Approval History tab.

Pediatric Idiopathic Growth-Hormone-Deficiency Therapy Research

Chronic pediatric idiopathic GHD therapy was the second FDA-approved indication for sermorelin. Geref (NDA 20-443, 0.5 mg and 1.0 mg base/vial, approved September 26, 1997) was authorized for the chronic treatment of idiopathic growth hormone deficiency in children with growth failure. The pivotal trial supporting the 1997 NDA was the Geref International Study Group study published by Thorner et al. in 1996^[7].

Thorner et al. 1996 enrolled 110 previously untreated prepubertal GH-deficient children in a multicenter open-label design and reported height velocity at baseline of 4.1 cm/year increasing to 8.0 cm/year at six months and 7.2 cm/year at 12 months, with a 74% good-response rate at six months and no excessive IGF-1 generation or adverse changes in biochemical or hormonal analyses^[7]. Prakash and Goa 1999 reviewed the pediatric clinical program and contextualized the published height-velocity findings against recombinant human growth hormone (rhGH), noting that the rhGH velocity readouts were larger than the sermorelin readouts and positioning sermorelin as a secondary option in pediatric GHD rather than first-line therapy^[5]. This relative efficacy gap was a contributing factor in the 2008 commercial discontinuation.

Adult Age-Related GH-Axis Supplementation Research

Adult age-related GH-axis supplementation is an off-label use case that dominates contemporary compounded-sermorelin commerce but rests on a substantially thinner peer-reviewed evidence base than the approved pediatric indication. Two academic Phase 2 studies from 1997 are the anchor references.

Vittone et al. 1997 enrolled 19 men and women ages 55 to 71 in a 16-week subcutaneous nightly dosing protocol with a 4-week placebo lead-in^[8]. The investigators reported increases in nocturnal GH and IGF-1 in both sexes, increases in IGFBP-3 and GH-binding proteins, lean body mass increases in men, skin thickness increases in both sexes after 16 weeks, and no changes in testosterone levels^[8]. Khorram et al. 1997 enrolled 14 healthy age-advanced subjects in a 16-week protocol using [Nle27]GHRH(1-29)NH2, a closely related analog with norleucine substituted for methionine at position 27 to remove the Met-oxidation pathway, and reported changes in skin thickness, lean body mass, and wellbeing scores^[9].

Walker 2006 in Clinical Interventions in Aging argued for sermorelin as a physiological alternative to exogenous rhGH in adult-onset GH insufficiency, citing the preserved negative-feedback regulation via somatostatin, the episodic rather than continuous receptor signal, and the stimulation of endogenous pituitary reserve^[10]. Walker 2006 is a single-author narrative review, not a primary clinical trial, and is frequently cited in commercial copy as if it were a definitive efficacy demonstration. Across the published adult-aging literature, sample sizes (n=14 to 19) and trial durations (typically 16 weeks) remain small and short. No Phase 3 RCT in adult age-related GH-axis indications has been published.

GHRH-Analog Class Comparison Research

Sermorelin sits in a class of synthetic GHRH analogs that share the GHRH 1-29 backbone but differ at specific residues, the C-terminus, and (in some cases) carrier modifications. Class comparison work is central to interpreting the broader research literature.

Sermorelin is GHRH 1-29 with the native N-terminal Tyr-Ala dipeptide intact, an unmodified central sequence, and the C-terminal amide preserved from the native parent. CJC-1295 and Mod GRF 1-29 share the same 29-residue backbone but carry four protease-resistance substitutions: D-Ala at position 2 to block DPP-IV cleavage, Gln at position 8, Ala at position 15, and Leu at position 27 to eliminate the methionine oxidation hotspot^[3]. CJC-1295 with DAC adds a Lys30 residue carrying a maleimidopropionic-acid (MPA) tag that forms a covalent thioether with the free Cys34 residue of circulating serum albumin, extending the half-life from hours to approximately one to two weeks.

Tesamorelin (Egrifta, Theratechnologies, FDA-approved November 10, 2010) is the full 44-residue GHRH sequence with an N-terminal trans-3-hexenoyl modification that blocks DPP-IV cleavage at the N-terminus while retaining the parent length. Tesamorelin is the only currently-marketed FDA-approved GHRH analog in the United States, authorized for HIV-associated lipodystrophy. The Baker et al. 2012 cognition study (Arch Neurol PMID 22869065)^[11] and the Friedman et al. 2013 brain-GABA follow-up (PMID 23689947) used tesamorelin and not sermorelin. The two molecules are distinct in sequence length, N-terminal modification, pharmacokinetics, and approved indication. Commercial copy that cites the Baker 2012 cognition result for sermorelin is making a category error.

Discovery, Mechanism Characterization, and the Salk Program

The native parent hormone GHRH was characterized in 1982 from a pancreatic tumor source by two groups working in parallel at the Salk Institute for Biological Studies in La Jolla. Guillemin et al. 1982 in Science characterized the 44-amino-acid amidated form (GRF44) plus shorter GRF37 and GRF40 forms^[1]. Rivier et al. 1982 in Nature characterized a 40-amino-acid GH-releasing factor from a parallel pancreatic tumor^[2]. The two papers appeared within weeks of each other and represent independent confirmation of the molecule's identity.

Guillemin had received the 1977 Nobel Prize in Physiology or Medicine (jointly with Andrew V. Schally and Rosalyn S. Yalow) for the discovery of hypothalamic regulatory hormones, including thyrotropin-releasing hormone (TRH), gonadotropin-releasing hormone (GnRH), and somatostatin, before the GHRH characterization work. GHRH was the final major hypophysiotropic neurohormone to be characterized, completing approximately four decades of hypothalamic-releasing-factor identification.

Subsequent preclinical work by Brazeau, Ling, and Guillemin established that the N-terminal 1-29 fragment retained the full biological activity of the parent GHRH 1-44 in vitro at the somatotroph^[1]. This truncation became the chemical basis for sermorelin: the synthesis was substantially easier than the full 44-residue parent, and the bioactivity was preserved. Serono Laboratories (later Ares-Serono, then Merck Serono, then EMD Serono after the 2007 Merck KGaA acquisition) developed sermorelin acetate as Geref. The base-composition-of-matter patent family (US 4,517,181 and related) has now expired in full, with the molecule effectively in the public domain pharmacologically.

Approved-Drug History & Replication

Sermorelin is the only peptide in the contemporary RUO and compounded-peptide catalog with extant US FDA-approval history. Two approvals were issued by FDA to Serono / EMD Serono: Geref Diagnostic (NDA 19-863, 0.05 mg base/amp, December 28, 1990) for GH-deficiency diagnostic provocation testing, and Geref (NDA 20-443, 0.5 mg and 1.0 mg base/vial, September 26, 1997) for chronic pediatric idiopathic GHD therapy. The two NDAs cover different formulations, different indications, and different dose strengths.

EMD Serono announced commercial discontinuation in December 2008. Industry literature cites manufacturing-process difficulty at commercial scale for the active pharmaceutical ingredient as the reason. The FDA published a Federal Register determination on March 4, 2013 (78 FR 14104, notice 2013-04827) confirming that Geref was not withdrawn from sale for reasons of safety or effectiveness^[12]. The 2013 determination is the structural anchor for sermorelin's continued compoundability under the 503A 'component of FDA-approved drug product' pathway in 21 USC 353a(b)(1)(A)(i)^[13]. This pathway is distinct from the 503A bulks-list pathway that governs BPC-157, TB-500, CJC-1295, ipamorelin, and most other peptides in the RUO catalog.

A frequently miscited claim is that the FDA Pharmacy Compounding Advisory Committee (PCAC) voted on sermorelin at its October 29, 2024 meeting. PCAC did not vote on sermorelin. The substances reviewed at the October 29, 2024 meeting were ibutamoren mesylate, L-theanine, ipamorelin, and kisspeptin-10. Sermorelin participates in none of the recent PCAC bulks-list adjudications because its regulatory posture flows from the FDA-approval pathway rather than from bulks-list inclusion. The April 1, 2026 Watkins indictment (USA v. Justin Bradley Watkins, D. Utah, 1:26-cr-00015-DBB) named CJC-1295, BPC-157, TB-500, ipamorelin, GHK, GHK-Cu, NAD+, and the GLPs; sermorelin was conspicuously not named, consistent with the FDA-approval-pedigree interpretation. The World Anti-Doping Agency lists sermorelin under category S2.2.4 (Growth Hormone Releasing Factors), banned at all times with no Therapeutic Use Exemption pathway. A category error to flag: the Baker LD et al. 2012 cognition study in Archives of Neurology used tesamorelin, not sermorelin, despite frequent miscitation in commercial copy^[11].